Disease burden, disease manifestations and current treatment regimen of the SAPHO syndrome in Germany: Results from a nationwide patient survey

2014 ◽  
Vol 43 (6) ◽  
pp. 745-750 ◽  
Author(s):  
Matthias Witt ◽  
Johanna Meier ◽  
Ariane Hammitzsch ◽  
Fabian Proft ◽  
Hendrik Schulze-Koops ◽  
...  
Keyword(s):  
Treatment Regimen ◽  
Disease Burden ◽  
Patient Survey ◽  
Current Treatment ◽  
Sapho Syndrome ◽  
Current Treatment Regimen

scholarly journals Current Treatment Regimen for Breast Cancer

2020 ◽  
Vol 4 (7) ◽  
pp. 29-31
Author(s):  
Prathyoosh C ◽  
Karukakulam Sandra Dominic
Keyword(s):  
Breast Cancer ◽  
Treatment Regimen ◽  
Current Treatment ◽  
Current Treatment Regimen

Non-accidental Paracetamol Poisoning in an Eleven Month-old Child

1983 ◽  
Vol 2 (2) ◽  
pp. 317-319 ◽  
Author(s):  
C.J. Taylor ◽  
A.M. Betts
Keyword(s):  
Case Report ◽  
Treatment Regimen ◽  
Current Treatment ◽  
Active Management ◽  
Accidental Poisoning ◽  
Paracetamol Poisoning ◽  
Current Treatment Regimen ◽  
Common Precipitant ◽  
A Current

1 Although accidental poisoning of children with drugs and chemicals is a common precipitant for admission to hospital, the possibility of deliberate poisoning as an extension of 'the battered baby syndrome' is rarely considered. 2 Most children admitted following accidental ingestions require little active management other than induction of emesis. Reports of relatively large overdoses in infancy are rare, and protocols for management of such cases largely untried. This case report demonstrates the successful application of a current treatment regimen to an infant who had ingested a substantial quantity of paracetamol.

Mixed metabolic response on PET/CT in patients with metastatic breast cancer as an early predictor of disease progression.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e11522-e11522
Author(s):  
Urmi Sen ◽  
Huichung Tina Ling ◽  
Akansha Chhabra ◽  
Kent P Friedman ◽  
Amy Tiersten
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Disease Progression ◽  
Treatment Regimen ◽  
Fdg Pet ◽  
Metastatic Breast ◽  
Current Treatment ◽  
Pet Ct ◽  
Current Treatment Regimen ◽  
Pet Ct Scan

e11522 Background: It has been observed that patients undergoing systemic therapy for metastatic breast cancer (MBC) may demonstrate a mixed metabolic treatment response on FDG PET (MMTR) while maintaining stable disease on CT (SDCT). The purpose of this study is to determine (1) the clinical outcome of MBC patients demonstrating MMTR+SDCT who were maintained on the same treatment regimen and (2) the behavior of oncologists when faced with a report of MMTR+SDCT. Methods: All FDG PET/CT scan reports performed at one institution between 2006-2011 were searched and studies describing a MMTR also containing the term “breast cancer” were identified. MBC patients without other active malignancies were extracted from the search and scans were re-analyzed. MMTR was defined as a PET/CT scan demonstrating a minimum of 2 lesions with a SUVmax change of +25% or more combined with at least 2 lesions demonstrating a SUVmax change of -25% or more. The subset of patients with MMTR+SDCT (by anatomical RECIST criteria) who were maintained on their current treatment regimen was further examined to identify time to progression (TTP). Results: Thirty-two cases were identified that demonstrated MMTR+SDCT in metastatic breast cancer patients. No change in therapy occurred within 3 months of the scan in 9/32 patients. Of the 9 patients who were maintained on their current treatment regimen, 5 patients demonstrated subsequent disease progression at 3 (n=2), 5 (n=2), and 11 (n=1) months (mean TTP = 5.4 months, range 3-11 months). One patient remains stable at 16 months and 3 patients have insufficient follow-up. Therapy was changed immediately after the scan in the remaining 22 patients for various reasons including preference of the treating oncologists, treatment toxicities, increase in tumor markers, or clinical progression. Conclusions: MMTR+SDCT in patients with MBC predicted subsequent disease progression within 6 months in the majority of individuals. Oncologists commonly alter treatment regimen when faced with a report of MMTR+SDCT. Based on the observation of outcomes in patients who did not change therapy, this practice seems justified.

SAT0535 Diagnosis, Disease Burden and Disease Manifestations of the Sapho Syndrome in Germany: Results from a Nationwide Patient Survey

2013 ◽  
Vol 72 (Suppl 3) ◽  
pp. A763.1-A763
Author(s):  
M. Witt ◽  
J. Meier ◽  
F. Proft ◽  
H. Schulze-Koops ◽  
M. Grunke
Keyword(s):  
Disease Burden ◽  
Patient Survey ◽  
Sapho Syndrome

scholarly journals Assessment and associated factors of suicidal behaviour among cancer patients visiting the oncology outpatient unit in Mekelle oncologic clinics, Tigray, Ethiopia: a cross−sectional study

2020 ◽  
Author(s):  
abreha Tsegay Gebreselassie ◽  
workua mekonen metekiya ◽  
birhane gebrehiwot beyene
Keyword(s):  
Cancer Patients ◽  
Treatment Regimen ◽  
Suicidal Behavior ◽  
Suicidal Behaviour ◽  
Associated Factors ◽  
Cross Sectional Study ◽  
Current Treatment ◽  
Sectional Study ◽  
Cross Sectional ◽  
Current Treatment Regimen

Abstract Background Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. According to estimates from the International Agency for Research on Cancer, there will be 17.0 million new cancer cases in 2018 worldwide. Depression, age, sex, divorced, and hopelessness are of most factors can patient with cancer result in suicidal behaviour. The purpose of this study is to identify and associated factors of suicidal behaviour among cancer patients in Mekelle, Ethiopia. Methods The cross-sectional study design was employed with a total of 345 study subjects in Mekelle, Ethiopia. Suicidal behaviour was measured by the Suicidal Behavior Questionnaire-Revised (SBQ-R) scale. Bivariate and multiple logistic regression analyses were performed to determine between the explanatory and outcome variables. Results The magnitude of suicidal behaviour was 20%. Previously suicidal attempt [AOR = 31.466, 95% CI (14.552, 68.042), P < 0.0001] was associated factor whereas no comorbid physical illness [AOR = .0.363, 95% (0. 164, 0.806)] and current treatment regimen (surgery, radiotherapy and palliative care) were significantly protective factors for suicidal behavior. Conclusion No comorbid physical illness, suicide attempt and current treatment regimen were significant factors of suicidal behaviour. Oncologic professionals should assess patient suicidal risk assessment routinely and every professional focuses on management besides the medication.

scholarly journals Diabetic Peripheral Neuropathy: Epidemiology, Physiopathology, Diagnosis and Treatment

2019 ◽  
Vol 7 (1) ◽  
pp. 35-48
Author(s):  
Nazma Akter
Keyword(s):  
Neuropathic Pain ◽  
Peripheral Neuropathy ◽  
Diabetic Peripheral Neuropathy ◽  
Clinical Evidence ◽  
Current Treatment ◽  
Diabetic Patients ◽  
First Line ◽  
Diabetic Neuropathic Pain ◽  
Current Treatment Regimen ◽  
Limb Proprioception

Diabetic peripheral neuropathy (DPN) is a common complication of both type 1 and type 2 diabetes. It affects over 90% of the diabetic patients. It is widely accepted that the toxic effects of hyperglycemia play an important role in the development of this complication, but several other hypotheses have been postulated. It is typically characterized by significant deficits in tactile sensitivity, vibration sense, lower-limb proprioception, and kinesthesia. Painful DPN has been shown to be associated with significant reductions in overall quality of life, increased levels of anxiety and depression, sleep impairment, and greater gait variability. DPN is often misdiagnosed and inadequately treated. Clinical recognition of DPN is imperative for allowing timely symptom management to reduce the morbidity associated with this condition. The management of diabetic neuropathic pain consists basically in excluding other causes of painful peripheral neuropathy, improving glycemic control as a prophylactic therapy and using medications to alleviate pain. First line drugs for pain relief include anticonvulsants, such as pregabalin and gabapentin and antidepressants, especially those that act to inhibit the reuptake of serotonin and noradrenaline. In addition, there is experimental and clinical evidence that opioids can be helpful in pain control, mainly if associated with first line drugs. Other agents, including for topical application, such as capsaicin cream and lidocaine patches, have also been proposed to be useful as adjuvant in the control of diabetic neuropathic pain, but the clinical evidence is insufficient to support their use. The purpose of this review is to examine proposed mechanisms of DPN, summarize current treatment regimen. A better understanding of the mechanisms underlying diabetic neuropathic pain will contribute to the search of new therapies. Delta Med Col J. Jan 2019 7(1): 35-48

scholarly journals Rifabutin Acts in Synergy and Is Bactericidal with FrontlineMycobacterium abscessusAntibiotics Clarithromycin and Tigecycline, Suggesting a Potent Treatment Combination

2018 ◽  
Vol 62 (8) ◽  
Author(s):  
Mark Pryjma ◽  
Ján Burian ◽  
Charles J. Thompson
Keyword(s):  
Treatment Options ◽  
Multidrug Resistant ◽  
Current Treatment ◽  
Mycobacterium Abscessus ◽  
Triple Combination ◽  
Pulmonary Infections ◽  
Treatment Combination ◽  
Content Type ◽  
Current Treatment Regimen ◽  
Drug Regimens

ABSTRACTMycobacterium abscessusis a rapidly emerging mycobacterial pathogen causing dangerous pulmonary infections. Because these bacteria are intrinsically multidrug resistant, treatment options are limited and have questionable efficacy. The current treatment regimen relies on a combination of antibiotics, including clarithromycin paired with amikacin and either imipenem or cefoxitin. Tigecycline may be added when triple therapy is ineffective. We initially screened a library containing the majority of clinically available antibiotics for anti-M. abscessusactivity. The screen identified rifabutin, which was then investigated for its interactions withM. abscessusantibiotics used in drug regimens. Combination of rifabutin with either clarithromycin or tigecycline generated synergistic anti-M. abscessusactivity, dropping the rifabutin MIC below concentrations found in the lung. Importantly, these combinations generated bactericidal activity. The triple combination of clarithromycin, tigecycline, and rifabutin was also synergistic, and clinically relevant concentrations had a sterilizing effect onM. abscessuscultures. We suggest that combinations including rifabutin should be further investigated for treatment ofM. abscessuspulmonary infections.

scholarly journals MicroRNAs Regulate Cell Cycle and Cell Death Pathways in Glioblastoma

2021 ◽  
Vol 22 (24) ◽  
pp. 13550
Author(s):  
Isra Saif Eldin Eisa Sati ◽  
Ishwar Parhar
Keyword(s):  
Cell Cycle ◽  
Cell Cycle Control ◽  
Current Treatment ◽  
Clinical Settings ◽  
Resistance To Treatment ◽  
Cell Death Pathways ◽  
Proliferation And Apoptosis ◽  
Current Treatment Regimen ◽  
Research Findings ◽  
Mirnas Expression

Glioblastoma (GBM), a grade IV brain tumor, is known for its heterogenicity and its resistance to the current treatment regimen. Over the last few decades, a significant amount of new molecular and genetic findings has been reported regarding factors contributing to GBM’s development into a lethal phenotype and its overall poor prognosis. MicroRNA (miRNAs) are small non-coding sequences of RNA that regulate and influence the expression of multiple genes. Many research findings have highlighted the importance of miRNAs in facilitating and controlling normal biological functions, including cell differentiation, proliferation, and apoptosis. Furthermore, miRNAs’ ability to initiate and promote cancer development, directly or indirectly, has been shown in many types of cancer. There is a clear association between alteration in miRNAs expression in GBM’s ability to escape apoptosis, proliferation, and resistance to treatment. Further, miRNAs regulate the already altered pathways in GBM, including P53, RB, and PI3K-AKT pathways. Furthermore, miRNAs also contribute to autophagy at multiple stages. In this review, we summarize the functions of miRNAs in GBM pathways linked to dysregulation of cell cycle control, apoptosis and resistance to treatment, and the possible use of miRNAs in clinical settings as treatment and prediction biomarkers.

Sign in / Sign up

Export Citation Format

Share Document